Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Anti-Cancer Drugs|February 1, 1992
Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonistC Brambilla, A Escobedo, R Artioli, et al.Journal of Steroid Biochemistry|October 1, 1988
Antihormonal activities of 5 alpha-reductase and aromatase inhibitorsS Zoppi, M Cocconi, M J Lechuga, et al.Tumori|April 30, 1991
Medical castration with zoladex: a conservative approach to premenopausal breast cancerC Brambilla, A Escobedo, R Artioli, et al.Acta Endocrinologica|January 1, 1989
Growth hormone (GH) responsiveness to GHRH in normal adults is not affected by short-term gonadal blockadeL Lima, V Arce, N Lois, et al.Clinical Endocrinology|April 1, 1989
Reasons for the variability in growth hormone (GH) responses to GHRH challenge: the endogenous hypothalamic-somatotroph rhythm (HSR)J Devesa, L Lima, N Lois, et al.European Journal of Cancer (Oxford, England : 1990)|September 21, 2013
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trialsA M Molina, X Lin, B Korytowsky, et al.Acta Endocrinologica|January 1, 1988
Dopamine acts on acetylation of proopiomelanocortin-derived products in dog pituitaryF Facchinetti, R Perez-Fernandez, M O Toma, et al.Investigational New Drugs|May 23, 2012
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancerC Gómez-Martín, R Salazar, C Montagut, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic studyH J Groen, E G de Vries, W Wynendaele, et al.Investigational New Drugs|October 5, 2013
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancerK-W Lee, S R Park, D-Y Oh, et al.Pageof 2